Can-Fite After March 2026: Funding Layer, Dilution and the Warrant Stack

The main article argued that Can-Fite's 2026 story still runs through clinical progress, but that the active bottleneck remains financial. This follow-up isolates that point: what exactly the March 2026 transaction did to the capital structure, and what kind of dilution inventory it left behind.

The core point is straightforward: March 2026 did not solve the funding question. It swapped immediate liquidity pressure for a new, larger and cheaper warrant layer. The company received roughly $4.35 million of gross proceeds after the balance sheet date, but it also rebuilt a warrant overhang that is now almost the size of the entire current equity base.

It is also worth being precise about the cash framing. This is not a full all-in cash bridge of every cash use. The relevant disclosure here gives three anchors: year-end cash of $8.539 million, 2025 net operating cash outflow of $8.949 million, and roughly $4.35 million of gross proceeds raised after year-end. That is enough to understand why the deal was necessary, but not enough to claim that funding flexibility suddenly became comfortable.

What the March 2026 deal actually changed

The going-concern note explains why the move was needed in the first place. At the end of 2025, Can-Fite had $8.539 million of cash, cash equivalents and short-term deposits, against a net loss of $9.828 million and net operating cash outflow of $8.949 million for the year. The same note says explicitly that the relief to the going-concern issue depends on financing completed after the balance sheet date and on a contingency plan that includes deferring and reprioritizing development programs and cutting senior-management compensation if needed.

In other words, the March cash did not land on top of surplus liquidity. It was injected into a structure that had already disclosed that operating cash burn was not self-funding the business.

The mechanics were aggressive. On March 4, 2026, Can-Fite entered into an inducement letter for the immediate exercise of 795,869 ADSs from the July 2025 warrant package, at a reduced exercise price of $5.00 per ADS instead of $9.34 per ADS. In exchange, it granted the same holder new warrants for 1,591,738 ADSs at $5.00 per ADS. On top of that, the placement agent received warrants for 55,711 ADSs at $6.25 per ADS, alongside cash fees of 7% plus 1% of gross proceeds and another $91 thousand of other fees.

That is the heart of the thesis. This was not a plain warrant exercise that clears an old overhang off the stock. It replaced one overhang with a new and larger one. The company pulled cash forward, but it paid for that cash by resetting the investor's economics and by creating a fresh contingent funding layer for later.

The use of proceeds makes the point even sharper. The March press release does not point to a strategic acquisition or a business-model shift. The money is earmarked for research and development, clinical trials, working capital and general corporate purposes. This is a time-buying layer, not an end-state.

The warrant stack after March 2026

Note 9 shows 2,604,097 warrants to purchase ordinary shares outstanding at the end of 2025. But that is no longer the right number once March 2026 is folded in. The July 2025 common warrants, equal to 1,666,667 ordinary shares, were effectively exercised in March. They were replaced by 3,183,476 potential ordinary shares through the new warrants and another 111,422 potential ordinary shares through the new placement agent warrants.

After that adjustment, the open warrant inventory reaches 4,232,328 potential ordinary shares. Current market data already shows 4,285,093 ordinary shares outstanding and tradable. So above an equity base of just over 4.28 million shares sits another 4.23 million shares of warrant overhang. That is almost a one-for-one relationship.

What matters is not just the size, but the concentration. Roughly 75.2% of the current warrant stack comes from the new March 2026 warrants, and with the placement agent warrants from the same event the weight rises to about 77.9%. The center of gravity is no longer the older and more expensive legacy series. It sits in one recent financing package, with lower exercise prices and a much clearer read-through to future dilution.

That is exactly what a quick read can miss. On the surface, warrant exercises sound positive because they bring in cash. Here, this is not a clean removal of the overhang. It is a reshaping of it. The key warrant layer simply changed form, price and timing.

What the dilution means in practice

If all open warrants are exercised, the share count rises from 4,285,093 shares to 8,517,421 shares, even before taking employee options into account. Existing shareholders would then own only about 50.3% of the enlarged equity base. This is not marginal theoretical dilution. It is almost a full second storey on top of the current capital base.

The subtler point is that this dilution is not meant to hit in a single day, which is exactly why it also acts as both a financing ceiling and an interpretation ceiling. Any clinical or operating improvement that lifts the stock will immediately be filtered through the question of whether it brings the new warrant layer closer to exercise, not only through the question of whether it improves the underlying business.

That said, the opposite exaggeration should also be avoided. This layer has real funding value. If the new March 2026 warrants and the related placement agent warrants are exercised in full, they imply roughly $8.3 million of additional gross proceeds. So March 2026 did not create dilution alone. It also created a second financing option. But it is an option, not cash in the bank. It depends on share performance, on completing the resale registration statement process, and on investors being willing to fund the company again through that same structure.

Another important point is that the bottleneck is no longer legal or technical. At the November 2025 shareholder meeting, authorized share capital was increased to 14 million shares. Even after 4.285 million shares outstanding and another 4.232 million potential shares through warrants, there is still room inside that authorized ceiling. The question is no longer whether the company can issue, but at what economic cost it keeps funding itself.

Why this matters now

In a pre-revenue biotech, capital structure is not an accounting footnote. It is part of the thesis. Can-Fite cannot separate clinical progress from the way it buys time until that progress arrives. That is why the March 2026 deal has to be read in two layers at once.

Layer one: immediate liquidity risk came down. The year-end going-concern disclosure did not remain unanswered, and the company did raise new cash after the balance sheet date.

Layer two: the price of that relief was a reset of the dilution ceiling. Instead of leaving the stock with an older warrant inventory whose center of gravity sat higher, the company created a new layer concentrated in one very large series and at lower exercise prices.

That also explains why the market can read the same event in two very different ways. A reader focused only on liquidity will see a company that bought more time for its trials. A reader focused on the full capital structure will see a company where almost every rally can quickly reopen the funding-via-equity question through warrants. Both readings are true at the same time.

Conclusion

The March 2026 transaction was a necessary financing move, not a clean-up. It bought Can-Fite time, but it did so by replacing the July 2025 warrant layer with a new and larger one, leaving an open warrant stack that now almost matches the current equity base.

So the next test is not only clinical. It is also capital-structure driven. For the thesis to improve, the March cash has to last until the next meaningful milestone without forcing the company back into a similar financing structure too quickly. If that does not happen, the liquidity relief may end up looking like only a waystation on the road to more dilution.